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OBJECTIVE — Although a clear link between diabetic peripheral neuropathy (DPN) and
autonomicneuropathyisrecognized,therelationshipofautonomicneuropathywithsubtypesof
DPNislessclear.Thisstudyaimedtoinvestigatetherelationshipofautonomicneuropathywith
painless and painful DPN.
RESEARCH DESIGN AND METHODS — Eighty subjects (20 healthy volunteers, 20
with no DPN, 20 with painful DPN, 20 with painless DPN) underwent detailed neurophysio-
logical investigations (including conventional autonomic function tests [AFTs]) and spectral
analysis of short-term heart rate variability (HRV), which assesses sympathovagal modulation of
the heart rate. Various frequency-domain (including low frequency [LF], high frequency [HF],
and total power [TP]) and time-domain (standard deviation of all normal-to-normal R-R inter-
vals[SDNN]androotmeansquareofsuccessivedifferences[RMSSD])parameterswereassessed.
RESULTS — HRV analysis revealed signiﬁcant differences across the groups in LF, HF, TP,
SDNN, and RMSSD (ANOVA P  0.001). Subgroup analysis showed that compared with
painless DPN, painful DPN had signiﬁcantly lower HF (3.59  1.08 [means  SD] vs. 2.67 
1.56),TP(5.731.28vs.4.791.51),andSDNN(2.910.65vs.1.623.5),P0.05.No
signiﬁcant differences were seen between painless DPN and painful DPN using an AFT.
CONCLUSIONS — This study shows that painful DPN is associated with signiﬁcantly
greater autonomic dysfunction than painless DPN. These changes are only detected using spec-
tral analysis of HRV (a simple test based on a 5-min electrocardiogram recording), suggesting
that it is a more sensitive tool to detect autonomic dysfunction, which is still under-detected in
people with diabetes. The greater autonomic dysfunction seen in painful DPN may reﬂect more
predominant small ﬁber involvement and adds to the growing evidence of its role in the patho-
physiology of painful DPN.
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D
iabetic neuropathy is one of the
most frequent complications of di-
abetes. The prevalence of some
form of neuropathy has been reported to
be as high as 66% in type 1 diabetes and
59%intype2diabetes(1).Itisthesource
ofgreatdistress,disability,andpremature
death. It is the main initiating factor for
foot ulceration and the most common
cause of nontraumatic lower-limb ampu-
tation in the Western world (2). It is also
one of the more poorly understood com-
plications of diabetes.
Althoughaclearrelationshipbetween
diabetic peripheral neuropathy (DPN)
and cardiac autonomic neuropathy
(CAN) has been recognized, the nature of
the relationship of CAN with painless or
painful neuropathy was less clear. Re-
cently, there has been some evidence that
at the level of the peripheral nerve, local
autonomic dysfunction has an important
role to play in the generation of pain (3).
However, clinical studies looking to see if
this translates into more generalized au-
tonomic neuropathy have shown mixed
and often opposite results (4,5). Part of
the reason for this may be that all of these
studies used conventional autonomic
function tests (AFTs), which tend to de-
tect autonomic dysfunction only at more
advanced stages (6).
Over recent years, a number of differ-
ent techniques have been developed that
aremoresensitivemeasuresofautonomic
function and are therefore able to detect
subclinical abnormalities (7). One such
technique is spectral analysis of heart rate
variability (HRV). Short-term HRV analy-
sis is relatively quick and simple to carry
out because it is based on a 2- to 5-min
resting electrocardiogram (ECG) record-
ing. The recording is able to detect auto-
nomic dysfunction in subjects in whom
conventional AFTs are still normal (8).
The aim of this study was to deter-
mine if there are differences in autonomic
function between painful and painless
DPN using spectral analysis of HRV.
RESEARCH DESIGN AND
METHODS— Subjectswithtype1di-
abetes were divided into three groups (no
DPN, painless DPN, and painful DPN)
with 20 subjects recruited in each group.
In addition, 20 healthy volunteers were
recruited. All subjects were between 18
and 70 years old. Subjects with nondia-
betic neuropathies, a history of alcohol
excess, and signiﬁcant left ventricular
dysfunction ( New York Heart Associa-
tion Class III) or other cardiac problems
that precluded HRV analysis were ex-
cluded. All subjects gave written, in-
formed consent before participating in
the study, which had prior approval by
the South Shefﬁeld Regional Ethics
Committee.
Neuropathy assessment
Subjects underwent detailed neurophysi-
ological assessment to determine the
presence and severity of neuropathy. The
presence of painful symptoms was es-
tablished using the McGill pain ques-
tionnaire (9). Detailed neurological
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ria using the standard Neuropathy Im-
pairment Score (NIS) questionnaire (10).
Sensoryfunctionwasassessedbymeasur-
ing vibration and cooling detection
thresholds acquired from the dorsal as-
pectoftherightfootusingtheComputer-
Assisted Sensory Evaluation IV system
(CASE IV) (W.R. Electronics, Stillwater,
MN) and employing standard techniques
(11,12). In addition, nerve conduction
studies were carried out at a stable skin
temperature of 31°C and a room temper-
ature of 24°C using a Medelec electro-
physiological system (Synergy Oxford
Instruments, Oxford, U.K.). The follow-
ing nerve attributes were measured: 1)
sural sensory nerve action potentials and
conduction velocities and 2) common
peroneal and tibial motor nerve distal la-
tency, compound muscle action poten-
tial, and conduction velocity. Subjects
alsounderwentconventionalcardiacAFT
performedwithacomputer-assistedtech-
nique and evaluated using standard car-
diovascularreﬂextestsbasedonO’Brien’s
criteria: heart rate responses (R-R varia-
tion) 1) at rest, 2) during deep breathing,
3) during Valsalva maneuver, and 4)o n
standing (13).
Based on these clinical and neuro-
physiological assessments, diabetic sub-
jectsweredividedintothreegroups:1)no
DPN, consisting of asymptomatic sub-
jects with normal clinical and neurophys-
iological assessments; 2) painless DPN,
comprising subjects with both clinical
and neurophysiological abnormalities (at
least two abnormalities of neurophysio-
logic assessment) but no painful symp-
toms; and 3) painful DPN, with similar
clinical and neurophysiological abnor-
malities and painful symptoms for at least
6 months. A Neuropathy Composite
Score (NCS) derived from the assess-
ments described above (NIS of the lower
limbs plus seven tests of nerve function)
was calculated, a full description of
which has been published previously
(14,15). This scoring system takes into
account the neurological examination
and neurophysiological assessments:
the higher the NCS, the more severe the
neuropathy.
Spectral analysis of HRV
HRV describes the timing variation be-
tween consecutive heartbeats (measured
using the R-R interval on an ECG). The
regulation of HRV originates from both
sympathetic and parasympathetic ner-
vous systems, and thus HRV can be used
as a quantitative marker of autonomic
function (16,17). Spectral analysis of
HRV provides the basic information of
how power of R-R variation distributes as
a function of frequency. Three main
componentsaredistinguishedinaspec-
trum calculated from an R-R time series
derived from short-term ECG record-
ings: very low frequency (VLF), low fre-
quency (LF), and high frequency (HF)
components. In addition, various time-
domain measures can be calculated
based on the intervals between succes-
sive normal complexes, the so-called
normal-to-normal (NN) intervals. The
most common measures used include
the standard deviation of the NN inter-
val(SDNN)andtherootmeansquareof
Figure 1—Examples of spectral analysis of HRV showing the R-R variability tracing (top panel)
and frequency domain plot in a diabetic subject with no CAN (A) and severe CAN (B) (note the
virtual abolition of peak within the LF and HF range in severe CAN). FFT, fast Fourier
transformation.
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val (RMSSD) (16,18).
HRV analysis was based on the re-
cording of 5 min of ECG with the patient
resting in a supine position after a period
of adaptation. Subjects were advised to
refrain from any caffeine or alcohol for
12 h prior to the examination, and any
subjects with hypoglycemia in the pre-
ceding 24 h had their examination post-
poned. All examinations took place in the
morning. The equipment required con-
sisted of a standard ECG ampliﬁer, a de-
vice to convert the analog ECG signals
into a digital format, and a laptop com-
puter to process and analyze the ECG us-
ing in-house developed software for HRV
analysis(19).Thesoftwareanddigitalsig-
nal processing algorithms followed estab-
lished guidelines for HRV analysis (16).
Frequency-domain parameters of HRV an-
alyzedwerepowerintheVLFrange(0.04
Hz), LF range (0.04–0.15 Hz), HF range
(0.15–0.4 Hz), LF-to-HF ratio, and total
power (TP) of the spectrum (0.003–0.4
Hz). Time-domain parameters of HRV ana-
lyzed were SDNN and RMSSD. Figure 1
shows examples of the frequency-domain
analysis in a diabetic subject with no CAN
and one with severe CAN.
Statistical analysis
Allanalyseswereperformedusingthesta-
tistical package SPSS 14. All values are
described as means  SD for continuous
data and as percentages for categorical
data. HRV parameters were logarithmi-
cally transformed to adjust for skewness.
One-way ANOVA was used to compare
baseline characteristics between groups,
and least signiﬁcant difference post hoc
testing was used to compare differences
between groups. As age is recognized to
be a signiﬁcant inﬂuence on HRV, one-
way ANCOVA, with age as a covariate,
was used to assess the signiﬁcance of any
differences between the groups in the
AFT results. Pearson’s correlation was
used to study the linear relationship be-
tween HRV measurements and NCS.
RESULTS— Table 1 shows the base-
line characteristics of the groups. As
wouldbeexpected,subjectswithnoDPN
had better glycemic control, had better
systolic blood pressure, had fewer other
complications of diabetes, and were on
less drug therapy than both DPN groups.
Importantly, there was no signiﬁcant dif-
ference in the mean age of the groups,
which is recognized as a major con-
founder of HRV. Subgroup analysis
showed that there were no signiﬁcant dif-
ferences between painful and painless
DPN. In particular, there was no differ-
ence between them in terms of the sever-
ity of neuropathy as assessed by NCS. In
addition, apart from tibial motor nerve
distal latency, which was signiﬁcantly
higher in painless DPN (6.4  1.4 vs.
4.9  2.2 m/s, P  0.008), no signiﬁcant
differences were detected in individual
neurophysiological parameters between
painless and painful DPN.
Table2showstheresultsofconven-
tional AFT and HRV analysis in the
differentgroups.Onconventionalauto-
nomicfunctiontesting,asigniﬁcantdif-
ference was seen across the groups for
all R-R variability results. Post hoc sub-
group analysis, however, showed no
signiﬁcantdifferencescouldbedetected
between painless and painful DPN. Not
surprisingly, the majority of signiﬁcant
Figure 1—Continued.
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unteers or no DPN with the two DPN
groups.
HRV analysis revealed signiﬁcant
differencesacrossthegroupsforvarious
parameters using both time- and fre-
quency-domain analysis (Table 2). Post
hoc subgroup analysis showed the
group with painful DPN had signiﬁ-
cantly lower values compared with
painless DPN for HF (means  SD,
2.67 1.56vs.3.59 1.08,P  0.04),
TP (4.79  1.51 vs. 3.59  1.08, P 
0.02), and SDNN (1.62  3.5 vs.
2.91  0.65, P  0.04). In addition,
there were trends toward lower values
in painful DPN compared with painless
DPN for LF (3.31  1.49 vs. 4.12 
1.67, P  0.07) and RMSSD (2.16 
0.71 vs. 2.58  0.69, P  0.06). Sub-
jects with no DPN also had signiﬁcantly
lower HF values compared with healthy
volunteers (4.41  1.57 vs. 5.45 
1.29, P  0.02).
A signiﬁcant negative correlation was
noted between NCS and LF across all the
groups (r  0.64), HF (r  0.55), TP
(r  0.68), SDNN (r  0.64), and
RMSSD (r  0.54), P  0.001.
CONCLUSIONS — This study shows
that subjects with painful DPN have sig-
niﬁcantly greater autonomic dysfunction
thansubjectswithpainlessDPNinacare-
fully matched and well-characterized
population.Thesedifferencesareonlyde-
tected using spectral analysis of HRV. No
signiﬁcant differences were detected us-
ingconventionalAFT.Toourknowledge,
Table 1—Baseline characteristics of study subjects
Healthy volunteers No DPN Painless DPN Painful DPN P (ANOVA)
n 20 20 20 20
Age (years) 46.6  14.7 45.7  10 52  9.7 52.1  11.1 NS
BMI 27.9  9.2 28  8.3 28.9  4.5 29.1  6.8 NS
Duration of diabetes (years) — 23.3  13 27.1  11.4 20.3  9.4 NS
A1C (%) — 7.7  1.3 8.8  1.5 8.6  1.5 0.042
Total cholesterol (mmol/l) 4.7  0.6 4.5  0.7 4.5  0.9 4.1  0.8 NS
Systolic blood pressure (mmHg) 131  21 135  14 151  20 141  19 0.007
Diastolic blood pressure (mmHg) 80  77 7  97 9  47 7  8N S
Retinopathy (%) — 35 90 75 0.001
Albuminuria (%) — 10 44 47 0.02
Severity of neuropathy (Dyck’s score) 0.8  0.8 1.3  1.1 18.5  7.9 21.8  10.2 0.001
Cardiovascular disease (%) 5 5 10 20 NS
Hypertension (%) 20 30 85 70 0.001
-Blocker (%) 5 0 16 20 NS
ACE/angiotensin receptor blocker (%) 0 27 67 55 0.001
Statin (%) 10 50 75 85 0.001
Data are means  SD, unless otherwise indicated. NS, not signiﬁcant.
Table 2—Autonomic function test results using conventional methods and HRV analysis
Healthy volunteers No DN Painless DPN Painful DPN P (ANOVA)
n 20 20 20 20
Conventional autonomic
function tests
Resting heart rate (bpm) 65.4  14.9 68.6  13.6 67.3  8.8 70.3  8.6 NS
R-R variation (rest) 1.21  0.09 1.21  0.09 1.14  0.08 1.10  0.05 0.001
R-R variation (deep
breathing)
1.47  0.27 1.38  0.26 1.24  0.16 1.16  0.14 0.001
R-R variation (Valsalva) 1.49  0.24 1.71  0.32 1.37  0.16 1.37  0.14 0.001
R-R variation (standing) 1.46  0.25 1.38  0.22 1.27  0.25 1.21  0.19 0.02
HRV frequency domain analysis
(log-transformed values)
VLF 4.23  3.35 3.55  3.6 2.60  3.82 1.62  3.5 NS
LF 5.59  1.14 5.23  1.32 4.12  1.67 3.31  1.49 0.001
HF 5.45  1.29 4.41  1.57 3.59  1.08 2.67  1.56* 0.001
LF/HF 1.06  0.28 1.26  0.39 1.19  0.48 1.57  0.97 NS
TP 7.11  0.93 6.55  1.14 5.73  1.28 4.79  1.51* 0.001
HRV time-domain analysis
(log-transformed values)
SDNN 3.52  0.43 3.31  0.55 2.91  0.65 1.62  3.5* 0.001
RMSSD 3.39  0.54 2.99  0.72 2.58  0.69 2.16  0.71 0.001
Data are means  SD. *P  0.05 compared with painless DPN group. NS, not signiﬁcant.
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used to assess differences in autonomic
function in subtypes of DPN.
The detection of greater autonomic
dysfunction in painful DPN compared
with painless DPN has biological plausi-
bility.Bothpainsensationandautonomic
function are mediated by small poorly
myelinated and unmyelinated ﬁbers
(whereasthelargerﬁberstendtotransmit
sensations such as vibration and touch)
andarethereforemorelikelytobevulner-
able to the pathological processes that oc-
curindiabeticneuropathy.Sorensenetal.
(20)demonstratedthatpainfulDPNisas-
sociatedwithabnormalitiesinthesesmall
ﬁberswhentheyshoweditwasassociated
with lower intra-epidermal nerve ﬁber
density. In addition, there is a variety of
evidence that local autonomic dysfunc-
tion is leading to changes in epineural
blood ﬂow and may have an important
role to play in pain generation. We have
previouslyshownthatpatientswithacute
painful neuropathy, so called “insulin
neuritis,” have abnormal epineural vessel
anatomy and increased arterio-venous
shunting (21). More recently, Eaton et al.
(22) demonstrated increases in sural
nerve epineurial blood ﬂow in painful
DPN. Quattrini et al. (3) subsequently
showed impairment of acetylcholine-
induced foot skin vasodilator response in
painfulDPN.Whatislesscleariswhether
this local autonomic dysfunction is a re-
ﬂection of a more generalized autonomic
neuropathy given that previous studies
have been inconsistent. Young et al. (4)
showedthatsubjectswithpainfulDPNhad
a higher ratio of autonomic to electrophys-
iological abnormality compared with pain-
less DPN. In contrast, Veves et al. (5)
showed no difference in autonomic func-
tion between painful and painless DPN.
One of the reasons why previous
studies looking at generalized autonomic
function in painful DPN may have shown
mixed results is that they have generally
used conventional tests of autonomic
function (cardiovascular reﬂex tests),
which only pick up abnormalities in the
more advanced stages. Current recom-
mendations for the diagnosis of CAN are
based on a consensus statement from the
San Antonio Conference on Diabetic
Neuropathyin1988andinvolveabattery
of detailed cardiovascular reﬂex tests
(23).Theyrecommendthreetestsofheart
rate control, which were heart rate re-
sponse to 1) deep breathing, 2) standing,
and 3) the Valsalva maneuver. Two tests
of blood pressure control were also rec-
ommended by testing blood pressure re-
sponse to standing/passive tilting and
sustained handgrip. The majority of these
tests require specialist equipment and
training and are time-consuming to per-
form. An additional drawback is that they
require active subject participation and
compliance.
Spectral analysis of HRV, in contrast,
has several advantages over conventional
techniques. In addition to being a more
sensitive measure of autonomic dysfunc-
tion, it 1) is easy to perform with limited
specialist training, 2) does not require ex-
pensive and cumbersome equipment, 3)
is very quick to carry out, and 4)i sn o t
affected by subject variability.
Although the results of this study are
consistent with the hypothesis of auto-
nomic dysfunction being involved in the
pathophysiology of painful DPN, the
cross-sectional design means that
whether it has a direct role or is simply a
para-phenomenon is not yet clear. It
seems unlikely that this association is a
reﬂection of the severity of neuropathy
giventhattherewerenosigniﬁcantdiffer-
ences between painful and painless DPN
ineitherNCSorthemajorityofindividual
parametersofnervefunction.Inaddition,
as there were no subjects in the painful
DPN group without objective neuro-
pathic impairment (i.e., those most likely
to have isolated small ﬁber involvement),
no conclusions can be drawn about dif-
ferences in autonomic dysfunction in this
subgroup. Perhaps, however, the most
important message of this study for clini-
cal practice is that the presence of painful
symptomsshouldincreasethephysician’s
vigilance for the presence of autonomic
neuropathy, which still often goes
undetected.
One possible confounder to these re-
sults is the greater use of drugs that may
interfere with HRV in the DPN groups.
Pharmacological agents such as -block-
ers, ACE inhibitors, and calcium channel
blockers generally result in increases in
HRV(24).Therefore,ifanything,theirus-
age would lead to an underestimation of
the differences seen between the groups.
This is also true of drugs such as gaba-
pentin and selective serotonin re-uptake
inhibitors; tricyclic antidepressants on
the other hand can result in lower HRV
(25).Althoughﬁvesubjectsinthepainful
DPNgroupwereonatricyclicantidepres-
sant,removingthemfromtheanalysisdid
not substantially alter the results. None
of the subjects were on any other
sympathomimetics.
This study also demonstrated sub-
jects with no evidence of DPN had lower
HF compared with healthy volunteers.
No differences were detected between
these two groups using the conventional
tests. HF is thought to be a marker of
parasympatheticfunction,andtheseﬁnd-
ings suggest that it can be detected early
before any manifestation of symptoms
and when conventional tests are still nor-
mal. It also suggests that parasympathetic
autonomic dysfunction is the ﬁrst abnor-
mality to arise in the development of
CAN. This is consistent with previous
ﬁndings (8).
One of the unresolved mysteries in
regard to the pathogenesis of diabetic
complications remains the puzzle of why
some people develop severe chronic pain
while others have no pain or symptoms.
The assumption has been that DPN is not
a unitary condition but develops as a re-
sult of different disturbances within the
peripheral nervous system. The paradox
is that many studies have failed to detect
consistent differences between painful
and painless DPN at the level of the pe-
ripheral nerve (5). This was once again
demonstratedinthisstudy,wherenoma-
jor differences were detected between
painful and painless DPN on detailed
neurophysiological testing. This study
has clearly demonstrated that spectral
analysis of HRV, based only on a 5-min
ECGrecordingatrest,isahighlysensitive
marker of autonomic dysfunction. It has
detected differences in autonomic dys-
function between painful and painless
DPN,whichcannotbedetectedbycruder
conventional AFTs. Whether this greater
autonomicdysfunctionhasadirectroleto
play in the generation or persistence of
pain in DPN now needs to be the subject
of larger prospective studies.
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